How a combined qual quant approach provided our client with integral insights for continued product development in the HIV space
Our client was looking to develop novel HIV prevention products, and wanted to explore different formulation options.
They wanted to learn both the reactions to the novel formulations as well as the impact of out-of-pocket (OOP) costs. Research was required to explore physician and consumer interest and gauge the impact of these developments on new and existing products.
How patient insights were brought to life with graphic novel outputs
Our client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks. Their new product promised greater freedom from these acute attacks and therefore from the associated burden. The challenge was to understand why many patients remain on older therapy types and how the pathway to more modern therapy options, with better efficacy and side effect profiles, could be mapped out for physicians and patients. Our client further requested that insights from the research were brought to life in the insights workshop meeting in a new and impactful way.
How Paediatricians and GPs revealed key insights to help develop a science story for a child nutritional supplement
Our client needed to develop a science story in order to increase uptake for their child nutritional supplement. Research was required in order to define the patient target, frame the challenge of growth delays to be an effective call to action, articulate objectives for the product and the best way to express its value proposition.
How we helped our client to understand the opportunities across Asia and other emerging markets using interactive outputs
Our client needed to understand why the use of statins in type 2 diabetes patients in South Korea, China, Thailand and other developing countries is low / sub-optimal. Research was required to understand the diabetic patient journey in order to assess the opportunities to expand HCP knowledge on the importance of lipid lowering for type 2 diabetes patients. The client also wanted to explore the drivers and barriers which would influence uptake.
How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.